References
- Hallopeau MH. Sur une asphyxie locale des extremities avec polydactylite suppurative chronique et pousse’s ephemeres de dermatite pustuleuse disseminee et symetrique. Soc Fr Dermatol Syph Bull. 1890;1:39–45.
- Waller J, Wu J, Murase J, et al. Chronically painful right thumb with pustules and onycholysis. Diagnosis: acrodermatitis continua of Hallopeau. Clin Exp Dermatol. 2007;32:619–620.
- Adışen E, Özer İ, Temel B, et al. Ustekinumab for the treatment of acrodermatitis continua of Hallopeau refractory to anti-TNF agents. Dermatol Ther. 2017;30:e12460.
- Cymerman RM, Cohen DE. Treatment of acrodermatitis continua of hallopeau with ustekinumab as monotherapy. JAMA Dermatol. 2016;152:346–348.
- Saunier J, Debarbieux S, Jullien D, et al. Acrodermatitis continua of Hallopeau treated successfully with ustekinumab and acitretin after failure of tumor necrosis factor blockade and anakinra. Dermatology 2015;230:97–100.
- Sopkovich JA, Poulos GA, Wong HK. Acrodermatitis continua of hallopeau successfully treated with adalimumab. J Clin Aesthet Dermatol. 2012; 5:60–62.
- Furue K, Yamamura K, Tsuji G, et al. Highlighting interleukin-36 signalling in plaque psoriasis and pustular psoriasis. Acta Derm Venereol. 2018;98:5–13.
- Chiricozzi A. Pathogenic role of IL-17 in psoriasis and psoriatic arthritis. Actas Dermosifiliogr. 2014;105:9–20.
- Böhner A, Roenneberg S, Eyerich K, et al. Acute generalized pustular psoriasis treated with the IL-17A antibody secukinumab. JAMA Dermatol. 2016;152:482–484.
- Imafuku S, Honma M, Okubo Y, et al. Efficacy and safety of secukinumab in patients with generalized pustular psoriasis: a 52-week analysis from phase III open-label multicenter Japanese study. J Dermatol. 2016;43:1011–1017.
- Baron JA. Acrodermatitis of Hallopeau and erosive oral mucositis successfully treated with secukinumab. JAAD Case Rep. 2017;3:215–218.
- Muggli D, Maul JT, Anzengruber F, et al. Secukinumab for acrodermatitis continua of hallopeau. JAMA Dermatol. 2017;153:336–337.